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Neuropsychiatric disordersa b s t r a c t
Apathy has been recognized as a frequent symptom in multiple sclerosis (MS) but uncertainty remains
about its prevalence and clinical correlates. Therefore, the objective of this work was to assess the preva-
lence of apathy in patients with MS and to identify clinical and demographic correlates. A case-control
study with 30 patients and 30 healthy controls matched for age, gender and education was performed.
Apathy diagnosis was established using Robert et al.’s criteria. Additionally, apathy was assessed using
the 10-item short version of the clinical-rated Apathy Evaluation Scale (AES-C-10). The Beck
Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS), and Montreal Cognitive Assessment
(MoCA) were used to evaluate depression, fatigue and cognitive impairment, respectively. Apathy preva-
lence in MS patients was 43.3%. Patients with MS had higher AES-C-10 scores than controls (13.9 vs. 12.0,
p = 0.015). Patients with apathy presented a higher proportion of males (53.8% vs. 11.8%, p = 0.02), lower
educational level (53.8% vs. 11.8% of patients with up to 9 years of education), higher scores on cognitive
dimension of MFIS (18.0 vs. 8.0, p = 0.048) and BDI (13.0 vs. 7.0, p = 0.035) and worse performance on
MoCA (24.0 vs. 26.0, p = 0.028). Gender was the only independent predictor of apathy, with men present-
ing a higher risk compared to women (OR: 9.62; 95%CI: 1.02–90.61; p = 0.048). In conclusion, apathy is a
common neuropsychiatric disorder in MS and it is probably underdiagnosed. Male patients seem to have
an increased risk of apathy, and this finding may be related to the generally more unfavorable course of
MS in men.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
According to Marin [1], apathy is defined as lack of motivation
not attributable to diminished level of consciousness, cognitive
impairment or emotional distress. This author structured the clin-
ical expression of apathy around the concepts of reduced goal
directed behavior (lack of initiative), reduced goal directed cogni-
tion (lack of plans and goals and lack of concern about one’s own
health) and reduced emotional concomitants of goal directed
behaviors (flattened affect and emotional indifference) [1,2]. The
concept of apathy has undergone changes over the ages and there
is still no consensus on whether apathy should be considered pri-
marily a disorder of drive and motivation, a disorder of emotions,
or both [3]. Modern conceptualizations reflect efforts to reconcile
the cognitive, motor and behavioral dimensions of apathy [4].While cognitive dysfunction is well documented in multiple
sclerosis (MS), apathy and other behavioral syndromes have
received less attention and are generally not a part of the health
status assessment of patients with MS [5].
The results of a meta-analysis including 23 studies revealed that
apathy was one of the most common behavioral symptoms in MS,
with a prevalence rate of 22% [5]. However, Chiaravolloti et al. [6]
reported an apathy prevalence of 35% in their study.
The aetiology of the neuropsychiatric manifestations of MS is
poorly understood. Figved et al. [7] proposed that pathophysiolog-
ical changes affecting frontal-subcortical circuits and limbic struc-
tures contribute to apathy in patients with MS. More specifically,
apathy has been related to damage of the medial frontal-anterior
cingulate circuit, the so-called motivational circuit [8].
The aim of this study was to assess the prevalence of apathy in
patients with MS and to identify clinical and demographic vari-
ables associated with its occurrence.
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2.1. Subjects and controls
We recruited 30 consecutive patients with a diagnosis of MS
according to the 2010 revised McDonald criteria regularly followed
in our department. Patients were excluded from the present study
on the basis of the following criteria: primary progressive MS; his-
tory of relevant head trauma, medical, psychiatric or neurological
disorder (other than MS); severe depression; illiteracy, language
impairment, severe dementia or physical disability preventing cog-
nitive assessment; alcohol, drug, or substance abuse; and relapse
or steroid pulse treatment within 4 weeks preceding evaluation.
Thirty healthy controls were randomly selected from a conve-
nience sample, matched for age, gender and education. All the
patients and controls gave their written informed consent to par-
ticipate in the study, which was approved by the local Ethics
Committee.2.2. Demographic and clinical assessment
We collected information about demographic aspects (age, gen-
der, level of education) in all subjects and clinical data in MS
patients, namely MS subtype, disease duration, age of onset, age
at diagnosis, number of relapses in the previous year, current
disease-modifying therapy and neurological disability measured
by Expanded Disability Status Scale (EDSS).2.3. Assessment of apathy
An interview based on Robert et al.’s criteria [4] was used for
clinical diagnosis of apathy. According to these criteria, apathy is
a disorder of motivation that persists over time and should meet
the following requirements: firstly, diminished motivation must
be present for at least four weeks; secondly, two of the three
dimensions of apathy (reduced goal-directed behavior, goal-
directed cognitive activity, and emotions) must also be present;
thirdly, there should be functional impairments attributable to
the apathy; and finally, symptoms and states that mimic apathy
must be excluded.
To further assess apathy, the 10-item version of the clinical-
rated Apathy Evaluation Scale (AES-C-10) was administered to all
subjects. AES-C-10 was validated for the Portuguese population
by Caeiro and Ferro [9]. AES-C uses a 4 point, Likert-type scale:
‘‘Not at all characteristic” (4 points), ‘‘Slightly characteristic” (3
points), ‘‘Somewhat characteristic” (2 points) or ‘‘Very characteris-
tic” (1 point). AES-C ratings are based on the clinician’s best judg-
ment of the subject’s ‘‘thoughts, feelings and actions” during the
past 4 weeks [10]. To carry out this assessment, verbal and non-
verbal data must be evaluated. Results range from a minimum of
10 points to a maximum of 40 points, with higher scores indicating
more severe apathy. The clinician rater followed the Guidelines for
coding severity of apathy, developed by the original author of the
AES [11]. According to these specific instructions, the four response
options are defined as follows: not at all characteristic (none, no
examples given); slightly characteristic (trivial, questionable, mini-
mal, for example: ‘‘I guess so”, ‘‘May be a little”); somewhat charac-
teristic (moderate, definite, for example ‘‘Yes”, ‘‘Definitely”, ‘‘I enjoy
playing bridge and dancing”); Very characteristic (a great deal,
strongly, for example: ‘‘Oh yes, absolutely, I love it.”, or non-
verbal evidence of intensity such as vigorous head nodding; raising
amplitude or frequency of speech).2.4. Assessment of cognitive status, depression and fatigue
Global cognitive status was evaluated by the Portuguese version
of the Montreal Cognitive assessment (MoCA) [12], the presence of
clinically relevant depressive symptoms was determined by the
Portuguese version of Beck Depression Inventory (BDI) [13] and
the presence of fatigue was assessed using the Portuguese version
of the Modified Fatigue Impact Scale (MFIS) [14].
The BDI is a measure of self-reported depression severity con-
sisting in 21 multiple choice questions. Results range from 0 to
63, and cut-offs are applied as follows: 0–14 indicates no depres-
sion, 15–19 dysphoria, 20–29 mild depression, 30–45 moderate
depression and >45 severe depression.
The MFIS measures the impact of fatigue in quality of live as
perceived by the subject. The test contains 21 items and comprises
three levels of fatigue: physical (MFISphy), cognitive (MFIScog) and
psychological (MFISpsy). The global score (MFIStotal) ranges from
0 to 84, with higher scores indicating more fatigue. The cut-off
score beyond which the subject can be considered fatigued is 38.
2.5. Statistical analysis
The level of statistical significance was set at p < 0.05 for all
analyses.
Variables were checked for normality using Kolmogorov–Smir-
nov and histogram inspection. Qualitative variables are reported as
absolute (n) and relative frequencies (%), quantitative variables
with normal distribution as mean and standard deviation (SD),
and not normally distributed variables as median, first and third
quartiles.
Comparisons between two groups (patients versus controls and
patients with apathy versus patients without apathy) were made
using independent-samples T-test for normally distributed vari-
ables, Mann–Whitney U-test for quantitative variables not nor-
mally distributed and chi-square (v2) test or Fisher exact test
(when appropriate) for categorical variables.
A stepwise backward binary logistic regression model (entrance
criterion p < 0.05 and exit criterion p = 0.10) was used to determine
which demographic or clinical characteristics were predictors of
apathy as defined by Robert et al.’s criteria. Only significant vari-
ables in the univariate comparisons were carried forward into
the regression analyses.
Pearson’s correlation (or Spearman correlation if normality was
not assumed) was used to assess the correlation between AES-C-10
score and quantitative clinical variables. For categorical variables,
as gender and educational level a Mann–Whitney U-test was
performed.3. Results
There were no significant differences in age, gender distribution
and level of education between MS patients and healthy control
groups. The demographic characteristics of the whole sample are
shown in Table 1.
Regarding the clinical characteristics, 28 patients (93.3%) pre-
sented relapsing-remitting MS and 2 (6.7%) secondary progressive
MS. The mean age at onset of MS was 32.4 years (SD ± 9.1) and the
mean age at diagnosis was 34.6 years (SD ± 9.5). The mean disease
duration was 12.3 (SD ± 7.8) and the median number of relapses in
the previous year was 0 (0–1). The median EDSS was 2.5 (1.5–4.2).
The prevalence of apathy (based on Robert et al.’s criteria) in
patients with MS was 43.3%. Moreover, MS patients scored
significantly higher in AES-C-10, BDI and MFIS compared to
Table 1
Demographic characteristics of patients with multiple sclerosis and healthy controls








Female, n (%) 21 (70.0%) 17 (56.7%) 0.284
Education, n (%)
69 years 9 (30.0%) 5 (16.7%) 0.222
>9 years 21 (70.0%) 25 (83.3%)
P < 0.05 was considered statistically significant.
1stQ = first quartile, 3thQ = third quartile.
Table 2






AES-C-10 13.0 [12.0;17.0] 12.0 [10.8;14.0] 0.015
MFIStotal 35.5 [17.0;51.0] 6.0 [4.0;18.8] <0.001
MFISphy 19.0 [10.0;26.0] 4.0 [1.00;9.3] <0.001
MFISpsy 4.0 [1.0;5.0] 0.5 [0.0;2.0] <0.001
MFIScog 10.5 [5.5;19.3] 1.5 [0.0;8.3] <0.001
MoCA 25.0 [23.8;27.0] 27.0 [25.0;29.0] 0.020
BDI 8.0 [4.0;15.3] 5.0 [2.0;7.0] 0.006
1stQ = first quartile, 3thQ = third quartile, AES-C-10 = 10-item short version of the
clinical-rated Apathy Evaluation Scale, MFIScog = cognitive dimension of Modified
Fatigue Impact Scale, MFISphy = physical dimension of Modified Fatigue Impact
Scale, MFISpsy = psychological dimension of Modified Fatigue Impact Scale,
MFIStotal = global score of Modified Fatigue Impact Scale, MoCA = Montreal
Cognitive Assessment, BDI = Beck Depression Inventory.
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suggesting the presence of more apathy, more depression and
more fatigue in patients. MS patients had worse cognitive perfor-
mance than controls (significantly lower MoCA scores, p = 0.020).
Table 2 summarizes the performance of each group in all tests.
Compared to non-apathetic MS patients, MS patients with apa-
thy presented a higher proportion of male gender (53.8% vs. 11.8%,
p = 0.02) and lower educational level (53.8% vs. 11.8% of patients
with up to 9 years of education). Moreover, patients with apathy
presented significantly higher scores in MFIScog (p = 0.048) and
BDI (p = 0.035) and significantly lower scores in MoCA
(p = 0.028), corresponding to higher indexes of cognitive fatigueTable 3
Comparison of demographic and clinical data between MS patients with apathy and with
Variables




Male, n (%) 7 (53.8)
Education, n (%)
69 years 7 (53.8)
>9 years 6 (46.2)
Disease duration 13.0 [3.5;2
Age at onset 37.0 [26.0
Age at diagnosis 39.0 [26.5








1stQ = first quartile, 3thQ = third quartile, BDI = Beck Depression Inventory, EDSS = Exp
Impact Scale, MFISphy = physical dimension of Modified Fatigue Impact Scale, MFISpsy =
of Modified Fatigue Impact Scale, MoCA = Montreal Cognitive Assessment, MS = multipland depression, and to worse cognitive performance, respectively.
On the other hand, we found no statistically significant differences
for the other clinical variables such as age, disease duration, age at
onset, age at diagnosis, number of relapses, EDSS and the total,
physical or psychosocial dimensions of fatigue (Table 3).
Regarding the AES-C-10 score, we found that it was correlated
positively with scores on BDI (p = 0.025) and on cognitive subscale
of MFIS (p = 0.028), and negatively correlated with scores on MoCA
(p = 0.005). The other clinical and demographical variables were
not significantly correlated with the scores on AES-C-10 (Table 4).
Gender was also associated with AES-C-10 score, with male
patients presenting significantly higher scores (17.0 vs. 12.0,
p = 0.004) (Fig. 1).
On the other hand, we found no association with education
level (up to 9 years: median score of 16.0; >9 years: median score
of 12.0, p = 0.164).
In the multivariate analysis, gender was the only variable
retained as an independent predictor of apathy, with men present-
ing a significantly higher risk compared to women (OR:9.62; 95%
CI: 1.02–90.61; p = 0.048).
The frequency of apathy in male patients was 77.8% compared
to 28.6% in female patients (p = 0.02).4. Discussion
In the present study, the prevalence of apathy in patients with
MS was 43.3%, which is higher than previously reported in litera-
ture [5,6]. This finding is particularly striking considering that
the study population was composed mainly by patients with
relapsing-remitting MS subtype, with relatively mild disability
and short disease duration. The discrepancy in the reported preva-
lence of apathy in MS can be partially explained by the fact that in
most of the previous studies, patients are assessed simultaneously
for a wide range of neuropsychiatric disorders using multi-
symptom assessment methods, such as the Neuropsychiatric
Inventory and the Frontal Systems Behavior Scale. To our knowl-
edge, there was only one study that explored specifically the occur-
rence of apathy in MS patient using AES as a tool [15]. We might
speculate that the use of specific criteria for apathy and validated
scales would allow to increase sensitivity for diagnosing apathy
in patients with MS, and that this neuropsychiatric symptommight
be more frequent than previously reported.out apathy (based on Robert’s et al. diagnostic criteria)
ith apathy Patients without apathy
(n = 17)
p




2.0] 12.00 [7.0;15.5] 0.934
;42.5] 31.0 [26.0;33.0] 0.229
;44.0] 32.0 [26.0;37.5] 0.385
5] 0.0 [0.0;1.0] 0.229
5] 2.0 [1.5;4.8] 0.157
;56.5] 28.0 [16.0;43.0] 0.103
;26.5] 18 [9.0;26.0] 0.457
5] 4.0 [0.0;4.0] 0.183
4.5] 8.0 [4.0;16.0] 0.048
;25.5] 26.0 [24.5;27.5] 0.028
2.0] 7.0 [3.0;12.0] 0.035
anded Disability Status Scale, MFIScog = cognitive dimension of Modified Fatigue
psychological dimension of Modified Fatigue Impact Scale, MFIStotal = global score
e sclerosis
Table 4
Correlation between AES-C-10 scores and clinical variables
AES-C-10
r p
Disease duration 0.133 0.482
Age at onset 0.012 0.951
Age at diagnosis 0.085 0.654








AES-C-10 = 10-item short version of the clinical-rated Apathy Evaluation Scale,
BDI = Beck Depression Inventory, EDSS = Expanded Disability Status Scale,
MFIScog = cognitive dimension of Modified Fatigue Impact Scale, MFISphy = phys-
ical dimension of Modified Fatigue Impact Scale, MFISpsy = psychological dimen-
sion of Modified Fatigue Impact Scale, MFIStotal = global score of Modified Fatigue










Fig. 1. Scores on AES-C-10 according to gender in multiple sclerosis patients. Male
patients presented higher median scores in AES-C-10 compared to female patients,
indicating more severe apathy. AES-C-10 = 10-item short version of the clinical-
rated Apathy Evaluation Scale.
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occurrence of apathy in patients with MS. In fact, gender was the
only independent predictor of apathy with an almost ten-fold
higher risk in men as compared to women. Likewise, men pre-
sented higher AES-C-10 scores. Despite the lack of published data
on the prevalence of apathy by gender in MS, male gender was pre-
viously reported as a risk factor for apathy in other diseases,
namely Parkinsońs Disease [16], Alzheimeŕs Disease [17] and Vas-
cular Dementia [18]. Nevertheless, the underlying pathophysiology
of this gender effect remains unknown.
In MS, one can hypothesize that the higher prevalence of apathy
in males may be related to the generally more unfavorable course
of MS in this group [19,20]. Furthermore, a recent study showed
that both deep gray matter atrophy and cognitive dysfunction
were worse in males [21]. A proposed explanation is that estrogen
may serve as a protective factor in MS, as suggested by animal
models [22]. In addition, the gender variation reported in healthy
controls regarding neuroanatomy [23] and functional network
properties [24] may contribute to different cognitive and neu-
ropsychiatric manifestations of MS. However, this gender effect
on apathy in MS patients has not been reported so far and needs
validation.The differences found among the educational groups, with the
higher educated patients having lower prevalence of apathy, may
be related to the well-known concept of the cognitive reserve.
The greater intellectual enrichment attenuates the negative effect
of disease burden on cognitive and motivational status [25], and,
theoretically, may have the same effect on neuropsychiatric mani-
festations as apathy.
Finally, we found an association between apathy and cognitive
fatigue, depression and cognitive impairment. In 1994, Marin et al.
[26] highlighted the importance of differentiating between apathy
as one symptom comprising part of a larger syndrome, such as
depression or dementia, from apathy as a primary disorder. Our
findings are in line with more recent studies that define apathy
as a specific and independent neuropsychiatric syndrome distinct
from depression, fatigue or cognitive impairment, even though
these symptoms co-occur in some patients [27,28]. The hypotheses
that there is a shared biological substrate for these disorders has
already been put forward [29]. An attempt to better define the rela-
tionships between apathy, depression and cognitive performance
in MS is expected to generate greater knowledge about the patho-
physiology of these conditions. On the other hand, from a clinical
point of view, distinguishing these syndromes is important, since
it has therapeutic implications.
Finally, in this study apathy was not related with age of onset,
age of diagnosis, disease duration or EDSS. This finding has impor-
tant clinical implications by suggesting that apathy should be sus-
pected even in earlier stages of the disease or in mildly disabled
patients, as it might have a significant impact on the daily routines
of MS patients.
There are some limitations to this study to be considered.
Firstly, the cross-sectional design and the small sample size might
have prevented to fully examine the influence of the clinical and
demographic variables on apathy. Secondly, the patients presented
relatively mild disability and most of them had a relapsing-
remitting subtype of MS. Therefore, the results of the current study
are not fully applicable to all MS patients, especially to those with a
more disabling form of the disease and with a secondary progres-
sive subtype of MS. Therefore, these results should be replicated in
a larger sample of patients with MS. Lastly, the relationship
between apathy and treatment with different disease modifying
drugs was not explored.5. Conclusions
Apathy is a common neuropsychiatric syndrome in MS and it is
probably underdiagnosed. Therefore, we propose that the use of
screening and diagnostic tools for apathy should be a part of the
health status assessment in patients with MS.
Moreover, this is the first study reporting that male gender is
associated with an increased risk of apathy in MS.
Future studies analyzing the influence of the different MS dis-
ease modifying therapies on apathy and studies with MRI tech-
niques are required in order to better understand the
pathophysiology underlying apathy in MS, which eventually may
lead to the development of specific treatment strategies.Conflicts of Interest/Disclosures
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